Low-dose Ketamine vs Morphine for Vaso-occlusive Crisis in Sicklers
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This clinical trial will inform of the role of Low dose ketamine in the acute treatment of
severe painful sickle cell crisis in children in a day-case sickle cell centre. The primary
aim is to determine whether Low dose ketamine is non inferior to morphine in the management
of acute painful sickle cell crises. The specific objectives will be to determine the maximal
change in NRS pain score following administration of ketamine and to examine the safety
profile of ketamine compared to morphine in this population.
The investigators hypothesize that low dose ketamine will result in similar effective pain
control as morphine alone and will not be associated with an increase in adverse events.